School of Medicine, University of California, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
Am J Trop Med Hyg. 2021 Aug 9;105(4):884-889. doi: 10.4269/ajtmh.21-0365.
Evaluating cases of reinfection may offer some insight into areas for further investigation regarding durability of immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sixty cases of reinfection with viral sequencing were identified in PubMed, Embase, Web of Science, and medRxiv before May 1, 2021.Episodes of infection were separated by a median of 116 days. Severity of illness was greater among individuals reinfected within 90 days of initial infection, no asymptomatic initial cases developed severe reinfection, nearly half of cases had suspected escape variants, and nearly all individuals tested following reinfection were found to have detectable levels of anti-SARS-CoV-2 antibodies. This analysis is limited by the heterogeneous methods used among reports. Reinfection continues to be relatively rare. As the case rate presumably increases over time, this review will inform measurements to determine the natural history and causal determinants of reinfection in more rigorous observational cohort studies and other standardized surveillance approaches.
评估再感染病例可能为深入研究严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）免疫反应的持久性提供一些线索。在 2021 年 5 月 1 日之前，从 PubMed、Embase、Web of Science 和 medRxiv 中确定了 60 例通过病毒测序确认的再感染病例。感染发作之间的间隔中位数为 116 天。在初次感染后 90 天内再次感染的个体中，疾病的严重程度更高，最初没有无症状病例发展为严重再感染，近一半的病例有疑似逃逸变异株，几乎所有在再感染后接受检测的个体都被发现有可检测水平的抗 SARS-CoV-2 抗体。本分析受到报告中使用的不同方法的限制。再感染仍然相对罕见。随着病例率随着时间的推移而增加，本综述将为更严格的观察性队列研究和其他标准化监测方法中确定再感染的自然史和因果决定因素的测量提供信息。
